A Breakthrough in Antiviral Chewing Gum: Can It Stop the Spread of Influenza and Herpes?
A groundbreaking discovery in the world of antiviral research has scientists excited about the potential of a new type of chewing gum that could help combat the spread of influenza and herpes viruses. Researchers in the US and Finland have found that this special gum has the ability to “trap” and neutralize certain strains of these contagious viruses.
Herpes simplex viruses 1 and 2 (HSV-1/-2) are responsible for causing oral herpes, a common infection that affects millions of people worldwide. Despite its prevalence, there are limited preventive measures available to curb its transmission. This new antiviral gum could be a game-changer in this regard, especially as efforts to develop a herpes vaccine have faced challenges due to funding constraints.
The gum, made from lablab bean powder derived from the seeds of the Lablab purpureus species, contains a natural viral trap protein called FRIL. In laboratory experiments using a mechanical mouth model, chewing the gum released a significant amount of FRIL proteins, which were then tested for their ability to neutralize viruses.
The results were promising, showing that the saliva produced from chewing the gum had over 95 percent neutralization rates for H1N1 and H3N2 influenza viruses, as well as significant neutralization of HSV-1 and HSV-2, the most common herpes viruses.
Neutralization of viruses means that they are less likely to infect cells and replicate, reducing the viral load and lowering the chances of transmission. The researchers are optimistic about the potential of this antiviral gum in clinical studies to minimize virus transmission.
Building on previous research that showed the efficacy of antiviral gum in combatting SARS-CoV-2, the virus responsible for COVID-19, scientists are now exploring the potential of this gum in clinical trials for COVID-19 prevention. Additionally, studies have demonstrated the effectiveness of FRIL proteins in reducing levels of other influenza viruses, highlighting the broad spectrum antiviral properties of this natural compound.
As researchers continue to investigate the efficacy and safety of lablab bean powder in clinical trials, the potential of this antiviral gum to reduce viral transmission remains a promising development in the fight against infectious diseases. The study was published in Molecular Therapy.
